達力普控股(01921.HK)預計年度淨利不少於8000萬元 同比扭虧
格隆匯2月21日丨達力普控股(01921.HK)公佈,與截至2020年12月31日止淨虧損約人民幣1.18億同期比較,集團預期於截至2021年12月31日止年度扭虧為盈及將錄得不少於人民幣8,000萬的淨利潤。
主要原因如下:(1)COVID-19大流行的負面影響在中國逐漸減弱,集團營運逐漸恢復正常;(2)集團努力實現產品和目標市場的多元化,客户對於集團產品的需求增加,生產線利用率較上年同期顯着提升,及已經回覆至飽和水平;(3)集團技術改進與創新成果於生產過程上的運用,有助彌補大宗商品價格上漲對成本造成的影響;及(4)集團出口比去年同期大幅度增加,是帶動銷售收入顯著增加原因之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.